First china-manufactured proposed rituximab biosimilar met primary efficacy and safety endpoints in CD20-positive diffuse large B-cell lymphoma (generics) | |
Shi, Y.; Zhang, Q.; Han, X.; Song, Y.; Qin, Y.; Hong, X.; Ke, X.; Feng, J.; Wang, D.; Li, W. | |
2018 | |
卷号 | 29 |
会议录 | ANNALS OF ONCOLOGY |
语种 | 英语 |
URL标识 | 查看原文 |
ISSN号 | 0923-7534 |
内容类型 | 会议论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/3607879 |
专题 | 复旦大学上海医学院 |
推荐引用方式 GB/T 7714 | Shi, Y.,Zhang, Q.,Han, X.,et al. First china-manufactured proposed rituximab biosimilar met primary efficacy and safety endpoints in CD20-positive diffuse large B-cell lymphoma (generics)[C]. 见:. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论